File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum hepatitis B viral DNA in HBsAg-positive hepatocellular carcinoma treated with interferon or adriamycin

TitleSerum hepatitis B viral DNA in HBsAg-positive hepatocellular carcinoma treated with interferon or adriamycin
Authors
Issue Date1986
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bjc
Citation
British Journal Of Cancer, 1986, v. 54 n. 1, p. 67-73 How to Cite?
AbstractSera from 31 HBsAg-positive Chinese patients with inoperable hepatocellular carcinoma (HCC) were tested for hepatitis B virus DNA (HBV DNA) by means of dot hybridisation and Southern blot technique. HBV DNA probes were prepared from human plasma. Eighteen of the patients were HBeAb-positive, 12 were HBeAg-positive and one case had neither marker. Serial specimens were obtained from 16 cases over 5-42 weeks, while the patients were treated with recombinant leukocyte A interferom (rIFN-A) or adriamycin. Seven patients (2 HBeAg-positive, 5 HBeAb-positive) were positive for HBV DNA. In two patients HBV DNA and HBV DNA polymerase (DNAp) appeared in serum weeks after rIFN-A or adriamycin treatment was started. In two other cases, HBV DNA that was initially present disappeared during rIFN-A treatment. In a fifth patient HBV DNA persisting after adriamycin treatment diminished after change of treatment to rIFN-A. With one possible exception the HBV DNA detectable by Southern blot technique was composed chiefly of sequences 2.2-3.2 kb size indicating the presence of unintegrated DNA forms. DNAp activities were raised in the presence of HBV DNA in 4 patients. These findings show that HBV replication can be activated or suppressed in advanced HCC. Treatment with rIFN-A may have been effective in suppressing HBV DNA synthesis, but the number of cases studied was too small to arrive at a definite conclusion on this point.
Persistent Identifierhttp://hdl.handle.net/10722/161705
ISSN
2015 Impact Factor: 5.569
2015 SCImago Journal Rankings: 2.939
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLin, HJen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorWu, PCen_US
dc.date.accessioned2012-09-05T05:14:12Z-
dc.date.available2012-09-05T05:14:12Z-
dc.date.issued1986en_US
dc.identifier.citationBritish Journal Of Cancer, 1986, v. 54 n. 1, p. 67-73en_US
dc.identifier.issn0007-0920en_US
dc.identifier.urihttp://hdl.handle.net/10722/161705-
dc.description.abstractSera from 31 HBsAg-positive Chinese patients with inoperable hepatocellular carcinoma (HCC) were tested for hepatitis B virus DNA (HBV DNA) by means of dot hybridisation and Southern blot technique. HBV DNA probes were prepared from human plasma. Eighteen of the patients were HBeAb-positive, 12 were HBeAg-positive and one case had neither marker. Serial specimens were obtained from 16 cases over 5-42 weeks, while the patients were treated with recombinant leukocyte A interferom (rIFN-A) or adriamycin. Seven patients (2 HBeAg-positive, 5 HBeAb-positive) were positive for HBV DNA. In two patients HBV DNA and HBV DNA polymerase (DNAp) appeared in serum weeks after rIFN-A or adriamycin treatment was started. In two other cases, HBV DNA that was initially present disappeared during rIFN-A treatment. In a fifth patient HBV DNA persisting after adriamycin treatment diminished after change of treatment to rIFN-A. With one possible exception the HBV DNA detectable by Southern blot technique was composed chiefly of sequences 2.2-3.2 kb size indicating the presence of unintegrated DNA forms. DNAp activities were raised in the presence of HBV DNA in 4 patients. These findings show that HBV replication can be activated or suppressed in advanced HCC. Treatment with rIFN-A may have been effective in suppressing HBV DNA synthesis, but the number of cases studied was too small to arrive at a definite conclusion on this point.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bjcen_US
dc.relation.ispartofBritish Journal of Canceren_US
dc.subject.meshAgeden_US
dc.subject.meshBase Sequenceen_US
dc.subject.meshCarcinoma, Hepatocellular - Blood - Drug Therapyen_US
dc.subject.meshDna, Viral - Metabolismen_US
dc.subject.meshDoxorubicin - Therapeutic Useen_US
dc.subject.meshElectrophoresis, Agar Gelen_US
dc.subject.meshHepatitis B Surface Antigens - Analysisen_US
dc.subject.meshHepatitis B Virus - Metabolismen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon Type I - Therapeutic Useen_US
dc.subject.meshLiver Neoplasms - Blood - Drug Therapyen_US
dc.subject.meshNucleic Acid Hybridizationen_US
dc.titleSerum hepatitis B viral DNA in HBsAg-positive hepatocellular carcinoma treated with interferon or adriamycinen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1038/bjc.1986.153-
dc.identifier.pmid3015183-
dc.identifier.scopuseid_2-s2.0-0022591802en_US
dc.identifier.volume54en_US
dc.identifier.issue1en_US
dc.identifier.spage67en_US
dc.identifier.epage73en_US
dc.identifier.isiWOS:A1986D141000009-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLin, HJ=7405571292en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats